As the Ebola outbreak continues with deadly momentum, drugmakers are working at lightning speed to develop a vaccine.
Pfizer's Prevnar 13 currently dominates the list of the world's best-selling vaccines--and that won't be changing anytime soon, according to a new report from EvaluatePharma. In fact, it's expected to widen its lead, with sales growing more than 61% over the next 5+ years; by 2020, it will be generating nearly $4 billion more than runner up Pentacel from Sanofi, EP predicts.
As far as the rest of the list, however, EP anticipates a bit of shuffling. Merck's Gardasil, last year's No. 2 seller, will slide into third place to make room for Pentacel. And GlaxoSmithKline's Pediarix will inch up into fifth, knocking Merck's varicella jab Varivax out of the top 5.
Take a look at the specifics and check out how the 2020 forecasts stack up to the top 10 best-selling vaccines of 2013.
The vaccine market has long been dominated by the Big 3--Sanofi, Merck and GlaxoSmithKline--with Pfizer and Novartis trailing the trio on the list of revenue-generators. But things are changing at the top. The "go big or go home" mentality has sent Novartis packing, with the Swiss company selling GSK most of its vaccines unit earlier this year as it made moves to exit the space. Pfizer, on the other hand, is scouting for ways to bulk up, earlier this month listing AstraZeneca's vaccine assets among the benefits of a potential merger.
For now, though, behind Pfizer's market-leading Prevnar 13, it's jabs from the leading triumvirate that bring in the bulk of vaccine sales. Merck, in particular, took four of the 10 top-selling spots, with Glaxo and Sanofi nabbing two apiece.
POPULAR COMMENT THREADS
GlaxoSmithKline's vaccines unit will be getting a new look come next year, when it's expected to absorb the bulk of Novartis' vaccines lineup it bought for $7.1 billion back in April. It'll have some new management, too, with Moncef Slaoui in the chairman's role. And judging from the pharma giant's Q3 results, some change for the unit could be a good thing.
Sanofi's Pentacel, which protects children against 5 serious diseases, nabbed the No. 3 spot on the world's list of best-selling vaccines last year. Whether an investigational 6-in-1 combo from the French drugmaker and partner Merck can eventually match its success remains to be seen, but the pair is now one step closer to finding out.
Cancer vaccine developers have seen their fair share of disappointments, and failures have spurred some companies to test their treatments in smaller patient subpopulations. Now, researchers are narrowing their focus even further as they gear up to trial personalized cancer vaccines.
Flu shots are a driving sales force for more than a couple vaccine players. But could an oral alternative disrupt the flu vaccine market down the line?
To help show Americans just how important its flu vaccines are, Novartis has teamed up with entertainer Nick Cannon, who's advising consumers to prepare for flu season by getting their shots and stocking up on the Swiss pharma's over-the-counter remedy, Theraflu.
Sanofi may be trailing in the sprint toward a herpes vaccine, but a new collaboration may give it the boost it needs to stay in the game.
From Our Sister Sites
In this week's EuroBiotech Report, Google revealed further details of its $100 million (€79 million) European venture capital unit, which is hunting for biotechs and startups in other sectors from its digs in London. And more.
As concern mounts over the deadly Ebola epidemic, French scientists are developing a diagnostic tool that works similar to a home pregnancy test and can quickly identify the virus through a tiny fluid sample.